Internal Development Programs

Program Indication Preclinical Phase 1 Phase 2 Phase 3 Next Catalyst
XCART™ Platform B-Cell Non-Hodgkin Lymphoma
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
  • 5/2020: Research and Development Collaboration: Scripps Research


  • 2020: FDA INTERACT Meeting
  • 2020: Secure additional academic and development collaborations
  • 2021: Expected IND Filing
  • Goal to secure industry collaboration

We plan to apply the XCART technology platform to develop cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas, an area of significant unmet medical need. Non-Hodgkin lymphoma (NHL) is a cancer that originates in the lymphatic system, with approximately 75,000 new cases each year, and represents a $5 billion market opportunity.1

XCART: Initial Market Opportunity in NHL

Driving Development Through Academic Collaborations

Leveraging Development and Manufacturing Expertise for Patient-Specific Therapies

Announced Collaboration:

XCART: Proof of Mechanism in B-cell Lymphoma2

XCART-Designed CAR T Cells Selectively Kill Raji Cell Lines Expressing Patient- Specific Target BCRs

Utilizing XCART, two CD8+ CAR T cell lines were generated which can differentiate between the B-cell Receptors (BCRs) derived from two individual Follicular Lymphoma (FL) patients.

Anti-CD19 CART and FL1-CART have similar effects on tumor growth

Learn more about our XCART™ platform

  1. https://seer.cancer.gov/; 2: Crump, M et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017 Aug 3; 3: Market Reports World. GLOBAL NON-HODGKIN LYMPHOMA THERAPEUTICS MARKET - SEGMENTED BY TYPE OF TREATMENT - GROWTH, TRENDS AND FORECASTS (2018 - 2023); BioPharm Insight Surveillance, Epidemiology, and End Results (SEER) 9 registries, National Cancer Institute, 2017
  2. Stepanov A, et al. 14 November 2018. Autocrine-based selection of ligands for personalized CAR-T therapy of lymphoma. Sci Adv. 4(11):eaau4580